List view / Grid view
Despite the promise of gene therapies, automated red blood cell exchange (aRBCX) remains an underutilised therapy in the management of sickle cell disease (SCD). In this article, Dr Aaron Haubner and Carly Newton of Terumo Blood and Cell Technologies, highlight the urgent need for partnerships and equitable access to this…
Researchers at Texas A&M University have developed advanced vessel-chip technology that closely mimics the complex architecture of human blood vessels, offering a new potential platform for studying vascular diseases and accelerating drug discovery.
ELRIG has announced the keynote speakers for Drug Discovery 2025, its flagship life sciences event taking place in Liverpool, England this October.
Researchers at ETH Zurich in Switzerland have mapped the complex network cells use to repair their genetic material, revealing previously hidden vulnerabilities in cancer cells.
ELRIG, a UK-based scientific community driving innovation in drug discovery, has appointed biopharma leader Dr Del Trezise as its new Chair - signalling a bold new chapter for the organisation.
UK Biocentre has significantly expanded its sample storage capacity with the addition of Azenta's BioArc Ultra, adding space for 16 million more samples to support vital health research.
In this episode, we discuss the history of the AAPS Summer Scientific Forum, highlights from the 2024 event, and its goals for the future.
Developing cell therapies solely with healthy donor material can jeopardise clinical outcomes, introducing risks ranging from faulty preclinical data to manufacturing failures. We spoke to Priya Baraniak, CBO at OrganaBio, who advocates for early integration of diseased donor material, improved biobanking infrastructure, and cross-industry collaboration to develop more effective, patient-relevant…
As Senior Vice President and Head of Global Medical Affairs & Outcomes Research at the global healthcare company Organon, Charlotte Owen’s extensive work is advancing women’s healthcare and overcoming health inequities.
A biomaterial that improved hyaline cartilage repair could be used to avoid knee replacements and treat injuries and degenerative diseases.
Antibody Drug Conjugates (ADCs) are already deployed as part of the roster of oncology treatments, but here, Mike Ward, Head of Thought Leadership for Life Sciences & Healthcare, Clarivate, looks into their potential to help treat a whole range of other diseases and conditions. He discusses the barriers and enablers…
As part of our series highlighting women in STEM, we spoke to Juliet Williams, Head of Research at Kymera. She discusses what inspired her early passion for science, the power of mentorship and what excites her most about the future of targeted protein degradation – and its potential to deliver…
Mini-colons, which closely resemble in vivo tissue, were used for several applications, including the characterisation of anticancer drug toxicity profiles.
Scientists discovered that, depending on germline variation, CRISPR-based experiments can result in false negatives.
This report provides exclusive access to content on innovative screening methods to improve detection and diagnosis of prevalent conditions like cancer and metabolic disease, with expert insights from leading professionals in the field.
